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OBJECTIVES: The pandemic of 2009 H1N1 influenza A emerged in February 2009, with high morbidity and
mortality, and rapidly spread globally. Sa˜o Paulo was among the most affected areas in Brazil. This study
compares the clinical and epidemiological characteristics of influenza-like illness between outpatients and
hospitalized patients and evaluates the impact of oseltamivir therapy on the outcome of 2009 H1N1 influenza A
patients.
METHODS: This is a case series study comparing the clinical and epidemiological characteristics of influenza-like
illness between outpatients attended at Hospital Sa˜o Paulo in August 2009 (the peak of the first pandemic
wave) and those patients hospitalized between May and September 2009 (the entire first pandemic wave).
RESULTS: The 1651 patients evaluated were predominantly female (9276686, p,0.001) and aged 31.71¡16.42
years, with 148 reporting chronic pulmonary disease. Dyspnea was presented by 381 (23.4%) patients and was
more frequent among those aged 30 years or more (p,0.001). Hospitalization occurred at 3.73¡2.85 days, and
antiviral treatment started 2.27¡2.97 days after the onset of first symptoms. A delay of more than 5 days in
starting oseltamivir therapy was independently associated with hospitalization (p,0.001), a stay in the ICU
(p,0.001) and a higher risk of dying (OR = 28.1, 95% CI 2.81-280.2, p= 0.007).
CONCLUSION: The 2009 pandemic of H1N1 influenza A affected young adults, presented a significant disease
burden and produced severe cases with a significant fatality rate. However, promptly starting specific therapy
improved the outcome.
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& INTRODUCTION
The 2009 pandemic of H1N1 influenza A rapidly spread
globally, provoking significant morbidity and mortality in
specific groups, although it is now acknowledged not to be a
highly virulent strain (1,2).
Despite initial uncertainty about the effectiveness of
oseltamivir therapy, in the post-pandemic evaluation, it
became clear that the therapy should be indicated for all
patients with an influenza-like syndrome, presenting with
lower respiratory tract involvement and/or high-risk
conditions for complicated influenza disease. The therapy
should preferably be initiated within the first 48-72 hours
after symptom onset, although the treatment could be
beneficial even if started later (3).
The 2009 H1N1 morbidity and mortality were high in
Brazil during the first pandemic wave, and the State of Sa˜o
Paulo was one of the most affected areas (4). As of May
2009, the first cases of H1N1 influenza A infection were
referred to Hospital Sa˜o Paulo, a tertiary university health
center designated as one of the reference centers for treating
suspected H1N1 cases by the State of Sa˜o Paulo health
authorities. A special unit for outpatient attendance in
suspected H1N1 cases was opened, and more than 4000
patients were evaluated and treated throughout the first
pandemic wave.
The Ministry of Health authorities established a case
definition for severe respiratory disease and set conditions
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for hospitalization (5). Patients received antiviral treatment
if hospitalized, but oseltamivir prescription was not
recommended for non-hospitalized patients.
This study describes the epidemiological and clinical
aspects of ambulatory and hospitalized patients attended at
Hospital Sa˜o Paulo between May and September 2009 and
evaluates oseltamivir therapy in the outcome of 2009 H1N1
influenza A-infected patients.
& METHODS
Study Design
This is a case series study comparing the clinical and
epidemiological characteristics of influenza-like illness
between outpatients attended at Hospital Sa˜o Paulo in
August 2009 (the peak of the first pandemic wave) and
patients hospitalized between May and September 2009 (the
entire first pandemic wave). The study was approved by the
local Ethics Research Committee.
In agreement with official recommendations (5), patients
with acute respiratory disease, characterized by fever
(axillary temperature .38 C˚), cough and dyspnea, and
patients with acknowledged risk factors for complicated
influenza (such as pregnancy and cardiorespiratory or
immune-compromising diseases), were hospitalized. The
use of oseltamivir was recommended only for those patients
and was preferably started within the first 48 hours after the
onset of symptoms in suspected H1N1 cases, obeying the
above criteria.
Epidemiological and Clinical Data
Clinical and epidemiological data were obtained from
patients using a standardized questionnaire. Age, gender,
occupation, the presence of comorbidities and/or risk
factors (5), clinical findings at first attendance (for out-
patients) or clinical, radiological and laboratory findings
during the first 24 hours (for hospitalized patients), the need
for supplemental oxygen, antibiotic or antiviral use and the
clinical outcome (only for those hospitalized) were recorded
for analysis.
Sample Collection and H1N1 Diagnosis
A diagnosis of 2009 H1N1 influenza A infection was
confirmed in nasopharyngeal swab specimens following the
Centers for Disease Control and Prevention (CDC) protocol
(6), with primers and probes for influenza A, swine flu A,
swine H1 and RNaseP (SuperScript III, Invitrogen).
Statistical Analysis
Data were recorded and analyzed using StatisticaH 5.5 for
WindowsH. Descriptive statistics and comparisons between
outpatients’ and inpatients’ clinical and epidemiological
findings are presented. Continuous variables were com-
pared using the Mann-Whitney test, a t-test for independent
samples or ANOVA, as appropriate. Categorical variables
were compared using a Yates-corrected chi-square test or
Fisher’s exact test. Odds ratios (ORs) with the respective
95% confidence intervals (CIs) were calculated whenever
indicated. Multivariate regression analysis was performed
to verify the variables independently associated with a stay
in the intensive care unit (ICU) and death. The significance
level chosen was 5%.
& RESULTS
We assessed data from 1579 outpatients evaluated as
suspected cases of 2009 pandemic H1N1 in August 2009,
which is considered the peak of the first influenza pandemic
wave in Sa˜o Paulo city. This sample represents approxi-
mately 1/3 of the patients with influenza-like illness
attended at our sentinel hospital from May to September
2009. In addition, data from all 72 adolescent and adult
patients hospitalized between May and September 2009
were compared with the data from the outpatients
described above. The demographic and epidemiological
characteristics of the sample are shown in Table 1.
The patients were predominantly female (927 females and
686 males, p,0.001), without any difference in gender
distribution between outpatients and inpatients. The aver-
age age was 31.7 years (95% CI: 30.9-32.5 years), and the
hospitalized patients were older than the outpatients (37.2
years [95% CI: 32.9-41.4 years] x 31.44 years [95% CI: 30.6-
32.3 years], p= 0.004). In addition, patients aged 20-29 years
were significantly more affected than the other age classes
(p,0.001) among the outpatients, inpatients and confirmed
H1N1 cases (see Table 1).
A preexisting comorbidity was reported by 298 (18%)
patients, of which the most frequent was chronic lung
disease, in nearly 10% (148/1651). In addition, 228 (14%)
patients had at least one acknowledged risk factor, as
defined by the Brazilian health authorities (MS2009b), as 57
(25%) were pregnant women and 42 (18%) were healthcare
workers.
Dyspnea was reported by 381 (23%) patients and was
more frequently observed among patients aged 30-39 (30%),
50-59 (32%) and .60 (30%) years (p= 0.001). Notably, the
majority of patients presenting with dyspnea (289/381, 76%)
did not report a previous lung disease. Nevertheless,
dyspnea was present in 62% of patients with chronic lung
disease, who had a nearly sevenfold greater risk of
presenting with dyspnea compared to patients without
chronic lung disease (OR = 6.8, 95% CI: 4.8-9.7, p,0.001).
Table 2 shows other clinical, radiological and laboratory
findings for both outpatients and inpatients.
Hospitalized patients had more fever, cough and dyspnea
than outpatients, whereas the outpatients had more sore
throat, rhinorrhea, headache, myalgia and diarrhea. With
the exceptions of fever, myalgia and diarrhea (more
frequent in H1N1-positive patients), symptoms did not
differ between hospitalized H1N1-positive and H1N1-
negative patients. Additionally, H1N1-positive patients
had higher levels of AST and ALT than hospitalized
H1N1-negative patients and tended to have higher CPK
levels (see Table 2).
Chest radiography showed that confirmed H1N1 cases
had more interstitial infiltrates, whereas unconfirmed H1N1
presented more parenchymal condensation, although these
differences were not significant (see Table 2).
A laboratory evaluation of the patients in the first
24 hours of hospitalization revealed that hypoxemia tended
to be more pronounced among confirmed H1N1 patients
than unconfirmed H1N1 patients (PaO2: 63.8679.8, p= 0.085;
see Table 2). Hypoxemia also tended to be more frequent
among confirmed H1N1 patients when considering either
the proportion of patients with PaO2,80 (20/24, 83% x 17/
28, 61%, p= 0.067) or the proportion of patients with
SaO2,95% (18/24, 75% x 14/28, 50%, p= 0.058).
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The majority of hospitalized patients (91.7%) had a good
outcome, but 4 (5.5%) patients died. Three of the fatal cases
were H1N1 patients, and 2 had a pulmonary comorbidity.
However, only 21 (29%) of the 72 hospitalized patients had
previous pulmonary disease, of which 62% (13/21) had a
confirmed H1N1 infection. In contrast, 32/72 (44%) of the
hospitalized patients with an influenza-like syndrome were
confirmed H1N1 cases, of which 19/32 (60%) had no
pulmonary comorbidity. In addition, confirmed H1N1
patients tended to remain in the ICU longer (2569.8 days,
p= 0.116) than unconfirmed patients.
Overall, the average time from the onset of symptoms to
the first attendance was 2.1 days (95% CI: 1.9-2.4 days), with
a range of 0-15 days, whereas the average time between
symptom onset and hospitalization was 3.7 days (95% CI: 3-
4.4 days), with no difference between confirmed and
unconfirmed H1N1 patients (p= 0.836).
Oseltamivir was prescribed for 25% (405/1651) of
patients, and nearly 84% (340/405) of the prescriptions
were for outpatients. Nevertheless, hospitalized patients
were 33-fold more likely to receive oseltamivir than
outpatients (65/726340/1579; OR = 33.3, 95% CI: 15.1-73.3,
p,0.001), which reflected the MS recommendations regard-
ing H1N1 therapy at that time. In contrast, antibiotics were
prescribed for 15% (245/1651) of patients, with no differ-
ence between outpatients and hospitalized patients
(p= 0.915).
Oseltamivir was initiated 2.3 days (95% CI: 1.9-2.6 days)
after symptom onset, but approximately 13% of patients
only received antiviral therapy 5 or more days after
symptom onset.
As observed in Figure 1, the duration between the onset
of symptoms and the beginning of oseltamivir therapy was
consistently longer for patients who were hospitalized
(p,0.001), entered the ICU (p,0.001) or died (p= 0.006)
than for patients without these complications. In addition, a
delay of 5 or more days in starting oseltamivir therapy was
associated with hospitalization (p,0.001), a stay in the ICU
(p,0.001) and a higher risk of death (OR = 28.1, 95% CI: 2.8-
280.2, p= 0.005) in the univariate analysis. The delay was
also independently associated with a need to stay in the ICU
and death in the multivariate analysis, as shown in Table 3.
Table 3 shows the multivariate analysis results, correlat-
ing gender (male or female), age (in years), confirmed H1N1
infection (yes or no), previous lung disease (yes or no) and
the time between symptom onset and the initiation of
oseltamivir therapy (,5 or $5 days) to a stay in the ICU or
death, which were the outcome variables of interest. In the
analysis focusing on death, having stayed in the ICU (yes or
no) was also included in the multivariate panel.
As shown in Table 3, starting oseltamivir therapy 5 or
more days after the onset of first symptoms and having
stayed in the ICU were independently associated with death
(Panel A). As shown in Panel B, a time interval equal to or
longer than 5 days was also associated with having been
admitted to the ICU, although the chosen significance level
was not achieved (p= 0.064).
& DISCUSSION
The 2009 pandemic of H1N1 influenza virus emerged in
February 2009 and rapidly spread globally, with lethality
averaging 0.6% (0.0004-1.47%) (1). By that time, the majority
of Brazilian cases were still imported, mainly from
Argentina, the USA and Chile (7,8), and local transmission
was acknowledged by the Brazilian public health authorities
only on July 16, 2009 (4).
The 2009 H1N1 virus has joined the mix of seasonal
influenza viruses but still affects young adults and children
more severely than the seasonal flu, which kills more
Table 1 - Demographic and epidemiological characteristics of the patients.
Characteristics Outpatients n (%) Inpatients
n (%) p* H1N1 Non-H1N1 p#
Gender
Male 663 (43) 23 (32) 0.082 9 (28) 14 (35) 0.534
Female 878 (57) 49 (68) 23 (72) 26 (65)
Age (years)
0-9 91 (06) --- --- ---
10-19 205 (14) 8 (11) 3 (09) 5 (13)
20-29 537 (36) 24 (33) 9 (28) 15 (38)
30-39 246 (17) 14 (19) 0.035 7 (22) 7 (18) 0.138
40-49 179 (12) 8 (11) 5 (16) 3 (08)
50-59 133 (09) 10 (09) 7 (22) 3 (08)
$60 88 (06) 8 (11) 1 (03) 7 (18)
Comorbidities
None 1309 (95) 24 (08) 11 (24) 13 (25)
Cardiovascular disease 15 (01) 44 (14) 5 (11) 10 (20)
Chronic pulmonary disease 21 (02) 127 (42) ,0.001 13 (29) 8 (16) 0.065
Immunopathies 12 (01) 24 (08) 5 (11) 7 (14)
HIV infection 10 (01) 46 (15) 4 (09) 6 (12)
Other conditions 14 (01) 39 (13) 7 (16) 7 (14)
Risk Factors
None 1427 (92) 44 (50) 15 (54) 23 (74)
Healthcare workers 27 (02) 14 (16) 5 (18) 0 (00)
Pregnancy 41 (03) 15 (17) ,0.001 3 (11) 5 (16) 0.286
Tobaccoism 45 (03) 10 (11) 5 (18) 3 (10)
Obesity 16 (01) 5 (06) 0 (00) 0 (00)
*Comparison between outpatients and inpatients.
#Comparison between H1N1 and non-H1N1 inpatients.
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elderly people (9). Our data confirmed the great burden of
H1N1 infection among young adults (see Table 1).
The majority of patients attended during the pandemic
peak in Sa˜o Paulo presented with typical influenza-like
illness but had an unexpectedly high frequency of dyspnea.
Dyspnea was observed in 21% of outpatients and 82% of
inpatients (see Table 2), with the majority (76%) not
reporting any chronic respiratory disease. In addition,
patients with confirmed 2009 H1N1 infection had more
pronounced hypoxemia than non-H1N1 cases. Experi-
mentally, it has been shown that lung replication of the
2009 H1N1 virus is higher than that of seasonal influenza A
viruses (10,11).
In this study, the most frequent risk factor for complicated
2009 H1N1 infection was chronic lung disease, but most
attended patients had no reported comorbidity. This finding
is in agreement with worldwide clinical data on 2009 H1N1
infection, which show that 25-50% of 2009 H1N1 patients
who were hospitalized or died had no underlying comor-
bidities (12-16).
Although the efficacy of oseltamivir therapy is now
widely acknowledged (17), the therapy’s efficacy in pre-
venting hospitalizations and deaths related to mild infec-
tions caused by the 2009 H1N1 influenza virus remains
controversial (8,18-20). However, there is now a consensus
that treatment should be offered to 2009 H1N1-infected
individuals with a high risk of complicated influenza or
with signs of lower respiratory tract involvement.
Moreover, therapy should start as soon as possible after
symptom onset, regardless of the clinical severity at
presentation (3,21-23). This recommendation is due to
difficulties in recognizing patients who present with mild
infection that will evolve clinical complications within the
first 48 hours after presentation.
An important result of this study was that delaying
oseltamivir for 5 or more days after symptom onset was
independently related to higher risks of hospitalization,
staying in the ICU and death. Regarding death, despite the
large CI observed in the univariate analysis (95% CI: 2.8-
280.2), which could raise suspicions of the results being
unreliable, the average risk of death was increased nearly
30-fold (OR = 28.1) when treatment was delayed for 5 or
more days. Furthermore, the minimum of the 95% CI (2.8)
showed that the risk of death after delayed treatment
increased at least threefold, which was not only statistically
significant but also of utmost biological and medical
importance. In addition, this finding was confirmed in the
multivariate analysis. In fact, obtaining such an expressive
result, considering the low number of samples analyzed (4
deaths among 72 hospitalized patients, of whom only 69
had recorded data complete enough to remain in the final
multivariate analysis), and the result’s medical relevance
seem to us important enough to deserve publication. Yu
et al. (22) also noted that delaying oseltamivir therapy for
more than 5 days increased the risk of severe disease,
defined as dying or having stayed in the ICU. However, the
researchers did not analyze each endpoint independently.
This study has certain limitations that should be
discussed. First, this was a retrospective study describing
the clinical and epidemiological profiles of H1N1 patients
attended during the first pandemic wave in Sa˜o Paulo.
Second, it was not possible to confirm H1N1 infection in the
majority of outpatients due to national public health police
limitations. Therefore, several different influenza subtypes
and other respiratory viruses could have circulated at same
time, as previously shown (24,25). However, during the first
pandemic wave in Brazil, approximately 70% of the cases
of influenza-like syndromes with laboratory-confirmed
Table 2 - Clinical findings of patients attended during the first H1N1 epidemic wave in Sa˜o Paulo.
Characteristics Outpatients n (%) Inpatients
n (%) p*
H1N1
n (%)
Non-H1N1
n (%) p#
Symptoms
Fever 1011 (81) 67 (93) 0.016 32 (100) 35 (88) 0.047
Cough 1040 (89) 68 (95) ,0.001 29 (91) 39 (98) 0.442
Dyspnea 322 (21) 59 (82) ,0.001 26 (81) 33 (83) 0.986
Sore throat 581 (95) 23 (32) ,0.001 9 (28) 14 (35) 0.616
Rhinorrhea 511 (95) 22 (31) ,0.001 11 (34) 11 (28) 0.611
Myalgia 895 (98) 33 (46) ,0.001 23 (70) 12 (30) 0.001
Headache 459 (96) 20 (28) ,0.001 11 (34) 9 (23) 0.299
Diarrhea 53 (79) 7 (10) ,0.001 6 (19) 1 (3) 0.039
Clinical Findings
Altered oroscopy --- 60 (86) 28 (88) 32 (84) 0.745
Altered pulmonary auscultation --- 35 (49) 16 (50) 19 (54) 0.833
Respiratory frequency --- 27.1¡5.1 29.3¡16.4 0.487
Chest Radiography
Normal (or not performed) --- 43 (60) 17 (53) 26 (61)
Interstitial infiltrate --- 22 (31) 13 (41) 9 (23) 0.218
Focal condensation --- 7 (10) 2 (6) 5 (13)
Laboratory Findings
SaO2 90.3¡6.7 89.4¡12 0.752
PaO2 63.8¡16.7 79.8¡42.8 0.085
PaCO2 33.6¡7.7 34.3¡16.3 0.841
DHL 401¡430 271¡191 0.149
ALT 51¡36 27¡37 0.041
AST 69¡62 33¡34 0.019
CPK 465¡811 201¡448 0.185
*Comparison between outpatients and inpatients.
#Comparison between H1N1 and non-H1N1 inpatients.
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etiologies were due to 2009 pandemic influenza A of the
H1N1 strain (26).
Another limitation was that the outcome of antiviral-
treated outpatients could not be systematically assessed for
comparison due to lack of control of the medical reevalua-
tions. However, national regulations stated that, during the
pandemic, influenza outpatients with complications or
worsening of the initial clinical status should be reevaluated
at the same site of the first attendance, at least preventing
the loss of available complicated cases.
Therefore, despite the above-mentioned limitations, our
results are robust and indicate a truly harmful effect of
delaying the initiation of antiviral therapy in certain 2009
H1N1-infected patients, which is in accordance with current
medical knowledge. In addition, to the best of our knowl-
edge, this work is the first to be published that shows an
independent increase in the risk of death that is simply
related to delaying the beginning of antiviral therapy.
In conclusion, it is now clear that delaying oseltamivir
therapy for 5 or more days is related to an increased risk of
severe infection and death, primarily for patients who
develop lower respiratory tract involvement, such as
dyspnea and cough. Accordingly, oseltamivir therapy should
be started immediately for individuals at risk of complica-
tions or presenting with lower respiratory tract symptoms,
regardless of the severity of the initial clinical presentation, as
previously stated in the new policies regarding the treatment
of H1N1-infected patients in Brazil (23).
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